c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer

Pancreatic cancer ranks fourth among cancer-related deaths, with a 5-years overall survival rate being below 10%. Gemcitabine (dFdC) has been considered the first-line drug for patients with pancreatic cancer. However, the clinical effectiveness is less than 20% due to drug resistance. Most importan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jingjing, Huang, Min, Shen, Qinghong, Ding, Ming, Yu, Shaofang, Guo, Yajuan, Lin, Yuefang, Zheng, Yaqiu, Chen, Wenbo, Yan, Wenxin, Liu, Zhongqiu, Wang, Dawei, Hu, Ming, Lu, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108354/
https://www.ncbi.nlm.nih.gov/pubmed/35586061
http://dx.doi.org/10.3389/fphar.2022.851512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108354/
https://www.ncbi.nlm.nih.gov/pubmed/35586061
http://dx.doi.org/10.3389/fphar.2022.851512

Ejemplares similares